Novartis AG has successfully completed its acquisition of Regulus Therapeutics Inc., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.